Table 1 Demographics and clinical characteristics of dabigatran-treated patients enrolled in this study
Variables | Characteristics of the study population (n = 86) | Characteristics of the study population providing trough samples(n = 83) | Characteristics of the study population providing peak samples(n = 58) |
|---|---|---|---|
Male, n(%) | 49(56.98) | 48(57.83) | 31(53.44) |
Age(years), mean(SD) | 72.15 ± 9.17 | 72.12 ± 9.16 | 72.07 ± 9.27 |
BMI(kg/m2), mean(SD) | 25.01 ± 3.76 | 25.15 ± 3.75 | 24.71 ± 4.08 |
Creatinine clearance, mL/min | 70.44 ± 26.81 | 71.87 ± 26.66 | 69.82 ± 25.63 |
CHA2DS2-VASc, mean(SD) | 3.41 ± 1.69 | 3.36 ± 1.63 | 3.33 ± 1.74 |
HAS-BLED, mean(SD) | 1.15 ± 0.88 | 1.16 ± 0.89 | 1.02 ± 0.74 |
AST(U/L), mean(SD) | 22.84 ± 11.91 | 22.82 ± 12.09 | 22.86 ± 11.76 |
ALT(U/L), mean(SD) | 23.14 ± 16.55 | 22.84 ± 16.58 | 21.47 ± 16.52 |
History of hypertension, n(%) | 62(72.09) | 60(72.29) | 41(70.69) |
History of stroke, n(%) | 14(16.28) | 13(15.66) | 7(12.07) |
History of diabetes mellitus, n(%) | 23(26.74) | 22(26.51) | 14(24.14) |
Aspirin use, n(%) | 3(3.49) | 3(3.61) | 1(1.72) |
Clopidogrel use, n(%) | 3(3.49) | 3(3.61) | 1(1.72) |
Amiodarone use, n(%) | 4(4.65) | 4(4.82) | 2(3.44) |
Trough concentration(ng/mL), mean(SD) | 51.32 ± 38.63 (n = 83) | ||
Peak concentration(ng/mL), mean(SD) | 101.12 ± 56.3 (n = 58) | ||
Any ischemic event, n(%) | 9(10.47) | 9(10.84) | 3(5.17) |
Any bleeding, n(%) | 17(19.77) | 15(18.07) | 14(24.17) |
Major bleeding, n(%) | 4(4.65) | 4(4.82) | 3(5.17) |
Minor bleeding, n(%) | 13(15.12) | 11(13.25) | 11(18.97) |